

**Additional File 1, Table 1.** Missing cause of death codes by cohort

Cohort	Total Deaths	Number of Deaths with missing Cause of Death Code	Proportion of Deaths with missing Cause of Death Code
<b>Co-RIS</b>	174	17	9.8%
<b>AHIVCOS</b>	294	30	10.2%
<b>SHCS</b>	384	54	14.1%
<b>PISCIS</b>	538	83	15.4%
<b>HOMER</b>	899	186	20.7%
<b>EuroSIDA</b>	210	45	21.4%
<b>Alberta</b>	140	38	27.1%
<b>DHK</b>	294	84	28.6%
<b>ATHENA</b>	1,006	321	31.9%
<b>Vanderbilt</b>	175	60	34.3%
<b>FHDH</b>	1,968	683	34.7%
<b>HAVACS</b>	109	39	35.8%
<b>AQUITAINE</b>	189	76	40.2%
<b>VACS</b>	<b>3,460</b>	<b>1,802</b>	<b>52.1%</b>
<b>Royal Free</b>	<b>123</b>	<b>70</b>	<b>56.9%</b>
<b>ICONA</b>	<b>257</b>	<b>158</b>	<b>61.5%</b>
<b>VACH</b>	<b>924</b>	<b>701</b>	<b>75.9%</b>
<b>BONN</b>	<b>37</b>	<b>30</b>	<b>81.1%</b>
<b>Cologne</b>	<b>99</b>	<b>91</b>	<b>91.9%</b>

Bold font denotes sites with >50% missing cause of death codes and therefore, exclusion in the sensitivity analysis (Table 5).

**Additional File 2, Table 2.** Unadjusted models for hazard ratios of cause-specific mortality

Type of death	N=6,712 coded deaths	HR (95% CI) Tuberculosis	HR (95% CI) Pneumocystis	HR (95% CI) Non-Hodgkin Lymphoma	HR (95% CI) All ADEs
<b>ADEs</b>	2,661	4.04 (3.43-4.75)	10.99 (9.72-12.44)	33.56 (29.74-37.88)	13.90 (12.86-15.01)
<b>All NADEs</b>	4,051	2.18 (1.83-2.59)	3.05 (2.56-3.63)	2.90 (2.16-3.91)	3.50 (3.26-3.75)
<b>NADE malignancy</b>	956	2.19 (1.53-3.13)	2.28 (1.51-3.45)	5.93 (3.85-9.14)	3.70 (3.21-4.26)
<b>Accident, Suicide, Overdose</b>	673	1.69 (1.04-2.74)	2.98 (1.93-4.60)	1.98 (0.82-4.76)	2.00 (1.63-2.44)
<b>Cardiovascular</b>	649	2.18 (1.41-3.37)	2.64 (1.65-4.22)	0.82 (0.20-3.27)	3.32 (2.78-3.96)
<b>NADE infection</b>	598	3.08 (2.10-4.54)	5.75 (4.09-8.09)	1.33 (0.43-4.14)	5.13 (4.33-6.07)
<b>Hepatic</b>	529	1.90 (1.14-3.18)	1.96 (1.08-3.57)	1.51 (0.48-4.68)	3.32 (2.73-4.05)
<b>Respiratory</b>	121	1.66 (0.53-5.21)	8.33 (4.36-15.92)	4.44 (1.10-17.95)	6.51 (4.52-9.37)
<b>Renal</b>	68	3.01 (0.95-9.58)	2.80 (0.69-11.45)	12.18 (3.83-38.77)	6.93 (4.27-11.23)
<b>Central nervous</b>	57	1.16 (0.16-8.41)	1.65 (0.23-11.93)	*	4.57 (2.61-7.99)
<b>Metabolic</b>	41	5.15 (1.59-16.68)	*	*	3.19 (1.57-6.51)
<b>NADE, Other</b>	359	1.87 (1.00-3.50)	2.10 (1.05-4.25)	3.73 (1.54-9.02)	2.84 (2.21-3.64)

\*Denotes that no deaths occurred in these categories.

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; ADE, AIDS defining event; NADE, non-AIDS defining event

**Additional File 3, Table 3.** Adjusted models for hazard ratios of cause-specific mortality (non-marginal structural models)+

Type of death	N=6,712 coded deaths	aHR (95% CI)	aHR (95% CI)	aHR (95% CI)	aHR (95% CI)
		Tuberculosis	Pneumocystis	Non-Hodgkin Lymphoma	All ADEs
<b>ADEs</b>	2,661	4.07 (3.44-4.81)	8.81 (7.69-10.08)	40.76 (35.64-46.62)	15.40 (14.04-16.90)
<b>All NADEs</b>	4,051	1.89 (1.58-2.25)	2.22 (1.86-2.66)	2.94 (2.17-3.96)	2.68 (2.47-2.90)
<b>NADE malignancy</b>	956	1.87 (1.30-2.69)	1.75 (1.15-2.66)	5.44 (3.51-8.43)	2.77 (2.35-3.26)
<b>Accident, Suicide, Overdose</b>	673	1.60 (0.98-2.60)	2.35 (1.51-3.65)	2.34 (0.97-5.65)	1.73 (1.39-2.16)
<b>Cardiovascular</b>	649	1.86 (1.19-2.90)	1.76 (1.09-2.84)	0.85 (0.21-3.41)	2.13 (1.74-2.60)
<b>NADE infection</b>	598	2.36 (1.60-3.50)	3.46 (2.41-4.97)	1.80 (0.58-5.62)	3.52 (2.88-4.30)
<b>Hepatic</b>	529	1.48 (0.88-2.48)	1.40 (0.76-2.56)	1.66 (0.53-5.19)	2.70 (2.15-3.38)
<b>Respiratory</b>	121	1.41 (0.43-4.62)	6.93 (3.51-13.69)	3.07 (0.78-12.11)	4.80 (3.24-7.12)
<b>Renal</b>	68	2.59 (0.80-8.37)	1.71 (0.40-7.32)	10.38 (2.93-36.72)	5.25 (2.78-9.90)
<b>Central nervous</b>	57	1.15 (0.16-8.53)	1.07 (0.14-8.50)	*	3.38 (1.73-6.60)
<b>Metabolic</b>	41	3.49 (1.08-11.31)	*	*	1.88 (0.79-4.48)
<b>NADE, Other</b>	359	2.24 (1.18-4.26)	2.15 (1.06-4.36)	2.98 (1.20-7.38)	3.04 (2.29-4.02)

\*Denotes that no deaths occurred in these categories.

+Models were adjusted for baseline CD4+ count, baseline HIV-1 RNA, sex, HIV transmission risk group, age, calendar year of ART initiation, baseline ART regimen (PI/NNRTI/other), ADE at time of or prior to enrollment, and ART-CC cohort.

Abbreviations: aOR, adjusted hazard ratio; 95% CI, 95% confidence interval; ADE, AIDS defining event; NADE, non-AIDS defining event

**Additional File 4, Table 4.** Adjusted marginal structural models for hazard ratios of cause-specific mortality+  
(Excluding those with ADE at or prior to baseline)

Type of death	N=4,225 coded deaths	aHR (95% CI)	aHR (95% CI)	aHR (95% CI)	aHR (95% CI)
		Tuberculosis	Pneumocystis	Non-Hodgkin Lymphoma	All ADEs
<b>ADEs</b>	1,308	2.86 (2.23-3.68)	4.82 (3.93-5.91)	52.59 (42.64-64.13)	12.60 (10.26-15.48)
<b>All NADEs</b>	2,917	1.55 (1.21-1.98)	1.96 (1.50-2.56)	3.66 (2.54-5.28)	2.37 (2.10-2.67)
<b>NADE malignancy</b>	683	2.15 (1.35-3.43)	1.76 (0.95-3.28)	6.56 (3.79-11.35)	2.96 (2.32-3.77)
<b>Accident, Suicide, Overdose</b>	528	0.75 (0.34-1.67)	2.57 (1.40-4.69)	3.43 (1.30-9.07)	1.21 (0.86-1.70)
<b>Cardiovascular</b>	461	1.93 (1.08-3.46)	1.45 (0.71-2.98)	0.38 (0.05-2.72)	2.25 (1.67-3.02)
<b>NADE infection</b>	405	1.44 (0.83-2.50)	2.44 (1.43-4.19)	2.30 (0.50-10.49)	2.34 (1.69-3.24)
<b>Hepatic</b>	382	0.85 (0.37-1.97)	0.83 (0.30-2.27)	3.72 (1.17-11.82)	2.30 (1.68-3.15)
<b>Respiratory</b>	76	1.89 (0.53-6.73)	2.24 (0.68-7.36)	2.85 (0.70-11.60)	4.96 (2.69-9.16)
<b>Renal</b>	50	2.65 (0.53-13.10)	0.55 (0.07-4.21)	4.65 (0.83-25.88)	4.87 (1.83-12.95)
<b>Central nervous</b>	36	*	0.86 (0.10-7.01)	*	1.27 (0.44-3.65)
<b>Metabolic</b>	29	5.46 (1.71-17.48)	*	*	1.38 (0.54-3.57)
<b>NADE, Other</b>	267	1.45 (0.55-3.79)	4.02 (1.61-10.04)	3.92 (1.50-10.27)	3.51 (2.37-5.18)

\*Denotes that no deaths occurred in these categories.

+Models were adjusted for baseline CD4+ count, baseline HIV-1 RNA, sex, HIV transmission risk group, age, calendar year of ART initiation, baseline ART regimen (PI/NNRTI/other), ADE at time of or prior to enrollment, and ART-CC cohort.

Abbreviations: aHR, adjusted hazard ratio; 95% CI, 95% confidence interval; ADE, AIDS defining event; NADE, non-AIDS defining event